 25829-04      10 May 2018 3:41 PM   Proof Nine
Highlights
Disclaimer: This Annual Report and Accounts may contain forward-looking statements. These statements 
reflect the Board’s current view, are subject to a number of material risks and uncertainties and could 
change in the future. Factors that could cause or contribute to such changes include, but are not limited 
to, the general economic climate and market conditions, as well as specific factors relating to the financial 
or commercial prospects or performance of individual companies within the Group’s portfolio. Further 
details can be found in the Risk management section on pages 46 to 53.
Throughout this Annual Report and Accounts, the Group’s holdings in portfolio companies reflect the 
undiluted beneficial equity interest excluding debt, unless otherwise explicitly stated.
Our business & strategy 
Chairman’s summary 8
Market 11
Business model 14
Our strategy 16
Our performance 
Key performance indicators 18
Operational review 20
Portfolio review 23
Financial review 40
Risk management 46
Our business ethics and  
social responsibility 54
Highlights 1
Q&A with the CEO 2
Group at a glance 4
Overview 
Board of directors 62
Corporate governance statement 64
Committee reports 
Directors’ remuneration report  80
Report of the audit and  
risk committee 100
Other statutory 
Directors’ report 105
Statement of directors’  
responsibilities 107
Independent auditor’s report 110 
Group primary statements 
Consolidated statement of  
comprehensive income 116
Consolidated statement of  
financial position 117
Consolidated statement  
of cash flows 118
Consolidated statement of  
changes in equity 119
Group notes
Notes to the consolidated  
financial statements 120
Company statements 
Company balance sheet 167
Statement of changes in equity 168
Notes to the company 
financial statements 169
Company information 183
Strategic Report
Business Overview
Our Financials
Our Governance
What’s inside
2016 2015 2014
451.3
2013
706.5
2017
1,326.2
714.3
315.5
2016 2015 2014
9.7
2013
14.7
2017
6.6
0.6
5.5
Hard NAV
(£m)
Proceeds from  
sales of equity 
investments
(£m)
£1,326.2m
(2016: £706.5m)
£6.6m
(2016: £14.7m)
Stock Code: IPO   www.ipgroupplc.com
1
Strategic Report Business Overview
Portfolio highlights
 y Net portfolio gains of £94.2m 
(2016: £6.5m)
 y Fair value of portfolio: £1,130.6m 
(2016: £614.0m) including £352.2m fair 
value of acquired Touchstone portfolio
 y Capital provided by IP Group to  
portfolio companies and projects: 
£71.2m (2016: £69.7m), and £13.4m 
(2016: £nil) by Parkwalk Advisors.
 y Portfolio cash realisations: £6.6m  
(2016: £14.7m)
 y Total funds raised by portfolio 
companies of £315m (2016: £230m)
 y Istesso commences Phase 2a clinical 
trials for its lead programme in 
Rheumatoid Arthritis and expands its 
R&D collaboration with Janssen
 y Autifony Therapeutics signs €627.5m 
collaboration agreement with  
Boehringer Ingelheim
 y Diurnal receives positive CHMP opinion 
for Alkindi®, a precursor to market  
launch for its first product in Q2 2018
Financial and operational highlights
 y Net assets £1,508.5m (2016: £768.7m) 
 y Hard NAV £1,326.2m (2016: £706.5m)
 y Return on Hard NAV of £64.1m (2016: negative £7.6m); Return on 
Hard NAV excluding acquisition and restructuring costs £73.2m 
(2016: negative £7.2m)
 y Profit for the year £53.4m (2016: loss £14.8m)
 y Gross cash and deposits £326.3m (2016: £112.3m)
 y Increased scale and critical mass through all-share combination with 
Touchstone, integration progressing well
 y Acquisition of Parkwalk Advisors Ltd, UK’s leading growth EIS fund 
manager focused on university spin-outs
 y Launch of IP Group Australasia; nine new partnerships signed with 
leading universities in Australia and New Zealand
 y £181.0m (net) capital raise completed, including significant new 
shareholders from Australia, China, Singapore and the UK 
Post period end highlights
 y Oxford Nanopore completes £100m financing round in March, 
confirms orders of $23.5m in 2017 and signals 2018 order book to 
more than treble to $75m 
